Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $11.33 Consensus Target Price from Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been assigned a consensus rating of “Hold” from the ten analysts that are currently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $10.78.

A number of equities analysts recently commented on the company. Morgan Stanley restated an “equal weight” rating and set a $8.00 target price (down previously from $38.00) on shares of Zentalis Pharmaceuticals in a report on Tuesday, June 18th. Oppenheimer reaffirmed an “outperform” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Monday. UBS Group cut shares of Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $28.00 to $5.00 in a research report on Thursday, June 20th. Wells Fargo & Company lowered shares of Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $29.00 to $9.00 in a report on Tuesday, June 18th. Finally, Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 target price on the stock in a report on Monday, August 12th.

Zentalis Pharmaceuticals Trading Up 11.4 %

ZNTL stock opened at $4.10 on Friday. The stock has a market capitalization of $291.21 million, a price-to-earnings ratio of -1.23 and a beta of 1.70. The firm’s 50-day moving average price is $3.54 and its two-hundred day moving average price is $8.62. Zentalis Pharmaceuticals has a 12-month low of $2.83 and a 12-month high of $23.52.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Friday, August 9th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same quarter in the prior year, the firm posted ($1.85) earnings per share. Equities analysts predict that Zentalis Pharmaceuticals will post -2.95 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Algert Global LLC bought a new stake in Zentalis Pharmaceuticals in the second quarter worth $78,000. Decheng Capital LLC boosted its stake in Zentalis Pharmaceuticals by 46.2% in the 2nd quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock worth $12,558,000 after purchasing an additional 970,859 shares in the last quarter. Squarepoint Ops LLC grew its position in Zentalis Pharmaceuticals by 543.8% during the 2nd quarter. Squarepoint Ops LLC now owns 148,755 shares of the company’s stock valued at $608,000 after purchasing an additional 125,649 shares during the last quarter. Bank of Montreal Can bought a new stake in Zentalis Pharmaceuticals during the 2nd quarter valued at about $402,000. Finally, XTX Topco Ltd increased its stake in Zentalis Pharmaceuticals by 1,581.9% during the 2nd quarter. XTX Topco Ltd now owns 178,465 shares of the company’s stock valued at $730,000 after purchasing an additional 167,854 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.